Actively Recruiting

Phase 2
Age: 4Years - 6Years
All Genders
Healthy Volunteers
NCT05422508

Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st Varicella Vaccination

Led by Green Cross Corporation · Updated on 2024-01-24

230

Participants Needed

1

Research Sites

256 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

* Primary objective is to assess the safety of MG1111 until Day 42 using as 2nd vaccination * Secondary objective to assess the immunogenicity and safety of MG1111 using as 2nd vaccination

CONDITIONS

Official Title

Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st Varicella Vaccination

Who Can Participate

Age: 4Years - 6Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Healthy children between 4 and 6 years of age as of the date of written consent
  • History of 1st varicella vaccination at least 3 years before study vaccination
  • Parent or legal representative willing to provide written informed consent and able to comply with study requirements
  • Negative history of varicella infection
Not Eligible

You will not qualify if you...

  • Exposure to varicella patient at home, school, or childcare within 4 weeks before vaccination
  • History of two or more varicella vaccine injections
  • Acute fever (at least 38.0°C) within 72 hours before vaccination
  • Suspected allergy symptoms including systemic rash within 72 hours before vaccination
  • History of Guillain-Barre syndrome
  • Severe chronic disease deemed ineligible by Investigator
  • Hypersensitivity to ingredients like gelatin, neomycin, kanamycin, erythromycin
  • Active tuberculosis
  • Other vaccinations within 4 weeks before vaccination
  • Immunodeficiency history
  • Use of salicylates within 4 weeks before vaccination
  • Immune globulin, gamma globulin, or blood products within 44 weeks before vaccination
  • Immunosuppressant or immune modifying drugs within 12 weeks before vaccination
  • Use of anti-viral drugs within 4 weeks before vaccination
  • Participation in other clinical trials within 24 weeks before vaccination
  • Other clinically significant medical or psychological conditions deemed ineligible by Investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Korea University Ansan Hospital

Ansan, South Korea

Actively Recruiting

Loading map...

Research Team

H

Hye Won Shin

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

OTHER

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st Varicella Vaccination | DecenTrialz